My
Type 2 Diabetes “Topic Alert” at Medscape recently emailed “Treating
the Obese Diabetic,” an article
published in Expert Reviews in Clinical Pharmacology at www.expert-reviews.com. It is a thorough, comprehensive and, in my opinion,
balanced review of anti-diabetic pharmacological agents for the treatment of
the obese type 2 diabetic. It also, as so many articles in the mainstream
medical literature do these days, seems to me to make a big push to boost the
business of the bariatric surgery industry. They’ve got boat payments to make
and apparently are underemployed, as so many are today.
I
can spare you having to read the whole paper. The abstract is brief and to the
point. Here it is in its entirety:
“Type
2 diabetes and obesity are intimately linked; reduction of bodyweight improves
glycemic control, mortality and morbidity. Treating obesity in the diabetic is
hampered as some diabetic treatments lead to weight gain. Bariatric surgery is
currently the most effective antiobesity treatment and causes long-term
remission of diabetes in many patients. However, surgery has a high cost and is
associated with a significant risk of complications, and in practical terms
only limited numbers can undergo this therapy. The choice of pharmacological
agents suitable for treatment of diabetes and obesity is currently limited. The
glucagon-like peptide-1 receptor agonists improve glycemia and induce a modest
weight loss, but there are doubts over their long-term safety. New drugs such
as lorcaserin and phentermine/topiramate are being approved for obesity and
have modest, salutary effects on glycemia, but again long-term safety is
unclear. This article will also examine some future avenues for development,
including gut hormone analogues that promise to combine powerful weight
reduction with beneficial effects on glucose metabolism.”
The
only pharmacological agent
that gets a clean bill of health in this comprehensive review is metformin. All
the others come with qualifiers like weight gain (!) and doubts over their
long-term safety. Here is their review of metformin:
“Metformin,
as per current American Diabetes Association (ADA) and European Association for
the Study of Diabetes recommendations, is the first-line medication used for
those with Type 2 diabetes and has an established safety record. It inhibits
hepatic gluconeogenesis, and to a lesser extent glycogenolysis, but also
increases insulin sensitivity. The UKPDS 34 study suggested improved
cardiovascular (CV) outcomes in those taking metformin, although recent
meta-analyses have failed to confirm this. Metformin not only offers useful
glycemic control but has also been shown in some trials to induce weight loss,
although two meta-analyses comparing metformin to placebo have shown its
overall long-term effect appears to be weight neutral. Metformin has been in
use clinically since the 1950s (in the USA since 1995), so it has a
well-understood long-term safety profile with the most common side effects
being transient gastrointestinal symptoms. Lactic acidosis is a rare side
effect but cases have been reported in the literature.”
The
Expert Commentary is succinct and pithy. The first paragraph tells the story.
The rest of this section is also a good read.
“Faced
with a newly diagnosed obese diabetic patient in a real world setting, it is
important to ensure that the antidiabetic medications prescribed are effective
and safe, without inducing weight gain. Ideally, our therapeutic strategy would
utilize treatments with a long-term safety record that can induce weight loss
and have been shown to improve CV outcomes. The only two treatments that offer
this level of evidence at present are bariatric surgery and metformin.”
The
paper includes 204 references and has a very interesting forward-looking
“Five-year View” section near the end which is worth a look for any healthcare
professionals among my readers. The “Sidebar” titled “Key Issues” summarizes
the paper:
· Bariatric surgery
is currently the most effective route to tackle the linked pathologies of
diabetes and obesity. It produces durable weight loss and long-term remission
of diabetes. In addition, cardiovascular morbidity and overall mortality are
reduced in those diabetics who undergo surgery.
· Mechanistically,
the improvement in glycemia following some forms of bariatric surgery, such as
Roux-en-Y gastric bypass, may be driven by changes in gut hormone levels, thus
providing a potentially attractive target for future medical therapies to treat
diabesity.
· GLP-1 analogues produce significant weight
loss along with an improvement in glycemia. DPP-IV inhibitors are well
tolerated, effective and weight neutral. Neither therapy has a proven long-term
safety record nor definitive evidence of benefit on cardiovascular risks.
· Recent additions
to the US market are centrally acting lorcaserin and phentermine/topiramate.
Both are effective at producing limited weight loss and have minor effects on
glycemic control. Long-term safety data are lacking and they are still awaiting
European approval.
Sadly,
but understandably, this article treats only what the medical professional can
do to “treat the obese diabetic:” write multiple scripts or, in eligible cases,
recommend surgery. It does not address counseling the patient to change their
diet to reduce the one thing that causes elevated glucose in the first place (in
the disregulated metabolism): dietary carbohydrates.
If
you read this blog regularly, you know the drill. In persons with insulin
resistance, excess carbohydrates, and too much protein which can also be
glucogenic (convert to glucose), cause
elevated blood glucose. There is no “fix” for this condition once you have
developed it except to eat
many fewer carbs (and moderate amounts of protein). If you continue to eat a
“balanced diet,” even with progressively more anti-diabetic medications, you will lose the battle. Your
pancreas eventually will be unable to produce the extra insulin to transport
your blood glucose to your cells that won’t take them up, and you will
eventually become an insulin-dependent type 2 and/or develop the “inevitable
complications” of “inadequately treated” type 2 diabetes: increased morbidity
and mortality from a host of causes too tedious to mention.
So,
you can let your doctor “treat the obese diabetic” in the manner prescribed in
this paper, with the risks they frankly explain (and the outcomes I have
suggested above), or… you can change your diet and “treat” yourself.
It’s up to you.